Paclitaxel Injection Global Market Report 2024 - Paclitaxel Injection Market to Reach $9.85 Billion by 2028

News provided by

Feb 15, 2024, 18:30 ET

DUBLIN, Feb. 15, 2024 /PRNewswire/ -- The "Paclitaxel Injection Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

The paclitaxel injection market size has grown rapidly in recent years. It will grow from $5.26 billion in 2023 to $6.02 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. It will further grow to $9.85 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%.

The anticipated growth in the forecast period can be attributed to the adoption of personalized medicine approaches, the development of biosimilars, the increasing burden of cancer in the aging population, advancements in drug delivery systems, and changes in healthcare policies. Key trends in the forecast period encompass the integration of artificial intelligence in oncology, the expansion of telemedicine and remote healthcare services, technological innovations in drug delivery, the incorporation of drug delivery technologies, and the rise of biosimilars.

The anticipated rise in breast cancer cases is poised to drive the growth of the paclitaxel injection market in the future. Breast cancer, characterized by abnormal cell growth in the breast, often forming tumors, is a prevalent condition. Paclitaxel injection, a chemotherapy drug, is instrumental in treating breast cancer by binding to microtubules, disrupting the growth of cancer cells. According to the American Cancer Society's January 2023 estimate, approximately 297,790 new cases of invasive breast cancer are expected in the US, leading to an estimated 43,700 deaths in 2023. Thus, the increasing incidence of breast cancer is a significant factor propelling the growth of the paclitaxel injection market.

The growing overall incidence of cancer is expected to further boost the paclitaxel injection market. Factors such as increased tobacco and alcohol consumption contribute to the rise in cancer cases globally. Paclitaxel, a chemotherapy medication, is commonly employed in treating various cancers, including breast, lung, and ovarian cancers. As cancer incidence continues to escalate, the demand for chemotherapy, with paclitaxel as a vital component, is expected to increase. The National Cancer Institute's 2021 report indicates that cancer is a leading cause of death worldwide, with an estimated 1,806,590 new cases and 606,520 deaths in the US alone. By 2040, the annual number of cancer cases is projected to reach 29.5 million, resulting in 16.4 million cancer-related deaths. Therefore, the rising cancer incidence is a key driver for the growth of the paclitaxel injection market.

The existence of alternatives to paclitaxel injection products may pose a limitation to market growth. The development of alternative Paclitaxel nano-delivery systems is driven by the severe side effects associated with existing formulations. Alternative delivery systems have the potential to reduce side effects, challenging the market for conventional paclitaxel injection products. For instance, the FDA granted accelerated approval to dabrafenib in combination with trametinib for the treatment of solid tumors with the BRAF V600E mutation. Thus, the availability of alternatives presents a challenge to the paclitaxel injection market.

Key companies in the paclitaxel injection market are focusing on innovation, introducing advanced products featuring materials such as protein-bound particles (PBPs) to meet consumer needs. PBPs represent a drug delivery system that utilizes albumin, a naturally occurring blood protein, to bind to drugs. Apotex Corp launched Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxanes, offering an alternative for the treatment of non-small cell lung cancer and metastatic breast cancer.

The primary types of paclitaxel injection are natural paclitaxel and semi-synthetic paclitaxel. Natural paclitaxel is a tetracyclic diterpenoid initially extracted from sources such as the bark of the Pacific yew tree, Taxus brevifolia. It is available in various drug strengths, including 10mg/ml, 20mg/ml, and 30mg/ml, and is utilized for the treatment of various cancers such as breast cancer, prostate cancer, testicular cancer, non-small cell lung cancer, lung cancer, among others. These injections are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are used by end-users such as hospitals, clinics, and cancer research institutes.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

By Type: Natural Paclitaxel; Semi-synthetic Paclitaxel
By Drug Strength: 10mg/mL; 20mg/mL; 30mg/mL
By Indication: Breast Cancer; Prostate Cancer; Testicular Cancer; Non-Small Cell Lung Cancer; Lung Cancer; Other Indications
By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
By End User: Hospitals; Clinics; Cancer Research Institute

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Companies Profiled

Pfizer Inc.
Bristol-Myers Squibb Company
Fresenius Kabi Oncology Ltd.
Abbott Laboratories
Viatris Inc.
Teva Pharmaceutical Industries Limited
Sandoz International GmbH
Hospira Inc.
Dr. Reddy's Laboratories Ltd.
Apotex Inc.
Intas Pharmaceuticals Ltd.
Zydus Lifesciences Limited
Torrent Pharmaceuticals Ltd.
Luye Pharma Group
Biological E Limited
Alembic Pharmaceuticals Limited
Khandelwal Laboratories Pvt. Ltd.
Gland Pharma Limited
Abraxis Bio Science Inc.
Novasep Holding SAS
Sagent Pharmaceuticals Inc.
Hainan Haiyao Co Ltd.
Accord Healthcare Ltd.
Natco Pharma Limited
Strides Pharma Science Limited
Panacea Biotec Ltd.
American Regent Inc.
MSN Laboratories Pvt Ltd.
Hetero Drugs Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/t6wfbh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets